Quiet on the insider front: nobody at Sana Biotechnology, Inc. bought or sold SANA shares on the open market this past year.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters. Big money check: 211 institutions held SANA as of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jan 10, 2025 | FMR LLC | 10% Owner | Sell | 100,000 | $6.11 | $611K | SEC |
| Jan 10, 2025 | FMR LLC | 10% Owner | Sell | 164,912 | $6.71 | $1.1M | SEC |
| Jan 10, 2025 | FMR LLC | 10% Owner | Sell | 1,000 | $7.26 | $7K | SEC |
| Jan 10, 2025 | FMR LLC | 10% Owner | Sell | 25,000 | $6.50 | $162K | SEC |
| Sep 26, 2024 | Mulligan Richard | Director | Sell | 150,000 | $4.08 | $612K | SEC |
| Sep 26, 2024 | Mulligan Richard | Director | Sell | 150,000 | $3.89 | $584K | SEC |
| Mar 11, 2024 | Yang Patrick Y | Director | Sell | 25,000 | $9.45 | $236K | SEC |
| Feb 12, 2024 | NELSEN ROBERT | Director | Buy | 727,272 | $5.50 | $4.0M | SEC |
| Feb 12, 2024 | NELSEN ROBERT | Director | Buy | 727,272 | $5.50 | $4.0M | SEC |
| Feb 12, 2024 | NELSEN ROBERT | Director | Buy | 363,637 | $5.50 | $2.0M | SEC |
| Feb 12, 2024 | Burow Kristina | 10% Owner | Buy | 727,272 | $5.50 | $4.0M | SEC |
| Feb 12, 2024 | Burow Kristina | 10% Owner | Buy | 727,272 | $5.50 | $4.0M | SEC |
| Feb 12, 2024 | Burow Kristina | 10% Owner | Buy | 363,637 | $5.50 | $2.0M | SEC |
| Feb 12, 2024 | ARCH Venture Fund X, L.P. | 10% Owner | Buy | 727,272 | $5.50 | $4.0M | SEC |
| Feb 12, 2024 | ARCH Venture Fund X, L.P. | 10% Owner | Buy | 727,272 | $5.50 | $4.0M | SEC |
There were no open-market insider trades in SANA in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
211 investment managers reported holding SANA in SEC Form 13F filings for Q2 2026.
No congressional trades in SANA were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).